Neuromodulation in Substance Use Disorders

Running, not enrolling · Not applicable

Conditions studied: Substance Use Disorder

In brief

The primary objective of this study is to assess the safety and feasibility of FUS neuromodulation in participants with OUD and/or other SUDs.

Key facts

Study ID

NCT07010016

Run by

Manish Ranjan

People needed

20

Starts

2025-08-07

Expected to finish

2028-07-30

Last updated by the study team

2025-10-20

Who can join

Age: 22 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Aged 22 - 60 years at time of enrollment.
• Fulfill current DSM-5 diagnostic criteria for OUD and/or other SUDs with at least a 2-year history.
• Currently receiving outpatient treatment from the WVU Comprehensive Opioid Addiction
• Treatment Program (COAT), Intensive Outpatient Program (IOP) or any other program which implements the COAT model; or receiving outpatient/inpatient/residential treatment from similar SUD treatment programs.
• Currently are under the care of a licensed psychiatrist or other mental health care provider, or a licensed addiction medicine specialist and agrees to promptly inform the investigator or the study staff of any change in these providers.
• Agrees to allow any and all forms of communication between the investigators/study staff and any healthcare provider who currently provides and/or has provided service to the patient/subject within at least two years of study enrollment for the purposes of eligibility confirmation or in case of a safety event.

You may not qualify if…

• Unable to undergo MR-imaging because of non-MR compatible implants or if candidates are uncomfortable in small spaces (have claustrophobia).
• History of any clinically significant neurological disorder.
• History of stroke or brain lesion with observable structural abnormalities in the targeted brain region.
• Clinically significant MRI abnormality indicative of a neurological condition or abnormality that may jeopardize the participant's safety, study conduct, or confound the participant's diagnostic assessments.
• An abnormal screening result that is considered clinically significant by a medically qualified research team member (i.e., laboratory tests, imaging findings).
• More than 30% of the skull area traversed by the sonication pathway is covered by scars, scalp disorders (e.g., eczema), or atrophy of the scalp.
• Past or present diagnosis of schizophrenia or psychotic disorder (assessed via SCID-
• History of medically verified suicide attempt within the past year.
• Meet the criteria for Cluster A or B Personality Disorders (assessed via SCID-5-PD).
• Current substance use treatment mandated by court of law.
• Subject who is currently participating in another clinical investigation with an active
• treatment arm.
• Subject is considered to be a poor surgical or study candidate, which may include, but is not limited to the following: any medical, social, or psychological problem that could complicate the required procedures and evaluations of the study in the judgment of the investigator

Where it is running

• WVU Rockefeller Neuroscience Institute — Morgantown, West Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.